CREATE Medicines

Private

Cambridge, MA clinical-stage biotech (formerly Myeloid Therapeutics) developing in vivo CAR therapies that reprogram immune cells (T cells, NK cells, myeloid cells) inside the body using an mRNA plus lipid nanoparticle delivery platform. Lead program CRT-402 targets CD19 for autoimmune disease.

Founders Daniel Getts, Siddhartha Mukherjee, Ronald Vale

CEO Daniel Getts

Company

Founded

2021

Headquarters

Cambridge, United States

Financials

Total Funding

$122M

Sectors

Healthtech Biotech

createmedicines.com

Funding History

1 round

Series B May 14, 2026

$122M

Newpath Partners (Lead) ARCH Venture Partners Hatteras Venture Partners Alexandria Venture Investments

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.